Arcus Biosciences, Inc. booked $33.0M in FY2025 revenue, contracting 35% year over year — slower than 78% of Healthcare companies we track, at a -1069.7% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.